Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine

Inclusion Criteria: * Men or women, between the ages of 18 to 65 years * Diagnosis of migraine, with or without aura * Experiences between 1 and 8 migraine attacks per month for the past 12 months Exclusion Criteria: * Inability to distinguish other headaches from migraine * Experiences headache of any kind at a frequency greater than or equal to 15 days per month * History of resistance to sumatriptan, or non-response to 2 or more other triptans, defined as subjects who have not responded to an adequate dose and duration of treatment * Current use of medication for migraine prophylaxis that has not been stable (no dose adjustment) for 30 days prior to screening * Chronic opioid therapy (\>3 consecutive days in the 30 days prior to screening)